Cat. No. 4206
Chemical Name: 4-(5-Methyl-3-phenylisoxazol-4-yl)b
Biological ActivitySelective and potent COX-2 inhibitor (in vitro IC50 values are 0.005 and 140 μM for human recombinant COX-2 and COX-1 respectively). Displays potent anti-inflammatory activity in vivo.
Licensing InformationSold for research purposes under agreement from Pfizer Inc.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Talley et al (2000) 4-[5-methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J.Med.Chem. 43 775. PMID: 10715145.
Walker et al (2001) A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors. Biochem.J. 357 709. PMID: 11463341.
Gierse et al (2005) Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity. J.Pharmacol.Exp.Ther. 312 1206. PMID: 15494548.
If you know of a relevant citation for this product please let us know.
Keywords: Valdecoxib, supplier, cyclooxygenase-2, COX-2, inhibitors, selective, potent, NSAIDs, pfizer, non-steroidal, anti-inflammatory
Find multiple products by catalog number
September 5 - 8, 2015